mRNA Lipid-Polymer Nanoparticle Core-Shell Design for Stable Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current mRNA delivery systems, particularly lipid nanoparticles (LNPs), are complex, unstable, and difficult to scale up due to their composition and synthesis challenges, leading to low stability and short in vivo half-life, which affects mRNA translation and expression efficiency.
Innovation Solution
A novel mRNA-lipid-polymer hybrid nanoparticles (LPNPs) delivery system comprising mRNA, a cationic molecule, a polymer, and a modified amphiphilic molecule, forming a stable core-shell structure through electrostatic and hydrophobic interactions, allowing for a simpler and more stable mRNA delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If lipid nanoparticles (LNPs) are used for mRNA delivery, then mRNA can be delivered into cells, but the system becomes complex requiring at least four different components
Solution Approach 1:
The patent combines multiple LNP components (ionizable lipid, cholesterol, phospholipid, PEG-lipid) into a single polymer molecule that possesses all necessary functional groups. This polymer integrates the cationic character for electrostatic binding, the structural framework for nanoparticle formation, and the surface modification capabilities, thereby reducing the system from four separate components to one multifunctional material.
Solution Approach 2:
The polymer molecule is designed to perform multiple functions simultaneously: it acts as the structural backbone of the nanoparticle, provides cationic charge for mRNA binding, enables endosomal escape through its ionizable groups, and offers surface modification sites for PEGylation. This multi-functional design eliminates the need for separate specialized components for each function.
2Adaptability or versatility
If traditional LNP components are used, then mRNA delivery is achieved, but the nanoparticles have low stability and short in vivo half-life
Solution Approach 1:
The patent employs a composite polymer structure incorporating multiple functional groups within a single molecular framework. The polymer combines rigid aromatic rings for structural stability with flexible aliphatic chains for membrane integration, and integrates ionizable amino groups for dynamic charge regulation. This composite molecular design creates nanoparticles with enhanced structural integrity and prolonged circulation time.
Solution Approach 2:
The polymer is designed with specific molecular weight, charge density, and hydrophobicity parameters that optimize nanoparticle stability. By adjusting the ratio of different functional groups within the polymer and controlling its molecular characteristics, the system achieves both structural rigidity for stability and fluidity for cellular uptake, while extending in vivo half-life through reduced clearance.
3Adaptability or versatility
If ionizable lipid molecules and auxiliary phospholipid molecules are used, then mRNA delivery is facilitated, but the synthesis and scaling up become difficult
Solution Approach 1:
The patent consolidates multiple lipid synthesis steps into a single polymer synthesis process. Instead of separately producing ionizable lipids, phospholipids, and PEG-lipids through complex multi-step chemistry, the polymer is synthesized in one reaction sequence, simplifying the manufacturing process and enabling easier scale-up while maintaining all necessary delivery functions.
Solution Approach 2:
The polymer is designed as a modular, easily synthesizable molecule that can be produced cost-effectively at scale. Its standardized structure allows for efficient manufacturing and potential generic production, reducing dependence on expensive, complex lipid chemistry and enabling more accessible, scalable mRNA delivery systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The LPNPs system achieves high mRNA encapsulation efficiency, stability, and transfection efficiency, with a simple and cost-effective production process, suitable for various therapeutic and diagnostic applications.
Implementation Method 1
the cationic molecule and negatively charged mRNA form a complex through electrostatic interaction
Implementation Method 2
the polymer is used to encapsulate the cationic molecule-mRNA complex to form a stable core structure
Implementation Method 3
the modified amphiphilic molecule is anchored to a surface of the core structure through hydrophobic interaction
Data Source
Figure 1a~2b
Figure 3~5b
Figure 6a~7b
AI summary
An mRNA/lipid-polymer hybrid nanoparticle delivery system, and a preparation method therefor and the use thereof. The delivery system comprises mRNA, cationic molecules, a polymer and modified amphiphilic molecules, wherein the cationic molecules and the negatively charged mRNA form a compound by means of electrostatic interaction, the polymer is used for accommodating the cationic molecule-mRNA compound, and the three form a stable core structure; and the modified amphiphilic molecules are anchored on the surface of the core structure by means of hydrophobic interaction, thereby forming a sphere-like core-shell structure.